ClinicalTrialStartPulse: Outside the US only, page 2 of 4
Records 51 to 200 of the 500 newest listed for this hub. Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
| Record | Phase | Conditions | Enrollment |
|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Phase 3 | Non Small Cell Lung Cancer | 436 |
| Qilu Pharmaceutical Co., Ltd. | Phase 3 | Extrapulmonary Neuroendocrine Carcinoma | 270 |
| AstraZeneca | Phase 2 | Overweight and Obesity | 166 |
| Brise Pharmaceuticals Co., Ltd. | Phase 3 | Migraine, With or Without Aura | 2079 |
| Keymed Biosciences Co.Ltd | Phase 2 | Advanced Solid Tumors | 128 |
| Sunshine Lake Pharma Co., Ltd. | Phase 2 | Chemotherapy-induced Anemia; Non-Myeloid Malignancy | 160 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2 | Herpes Zoster | 496 |
| Hoffmann-La Roche | Phase 3 | Influenza, Human; Respiratory Tract Infections; Post-exposure Prophylaxis | 325 |
| Jiangsu HengRui Medicine Co., Ltd. | Phase 2 | Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP) | 120 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 3 | Seasonal Allergic Rhinitis | 220 |
| Merck Sharp & Dohme LLC | Phase 3 | Papillomavirus Infections | 930 |
| ScandiBio Therapeutics AB | Phase 3 | Gout Disease | 336 |
| Sanofi | Phase 3 | Immunization; Healthy Volunteers; COVID-19 Immunization; Influenza Immunization | 6000 |
| SPH Sine Pharmaceutical Laboratories Co., Ltd. | Phase 2 | Bacterial Vaginosis (BV) | 150 |
| Hoffmann-La Roche | Phase 3 | Type 2 Diabetes Mellitus | 948 |
| Beijing Keymed Biosciences Co., Ltd. | Phase 2 | Perennial Allergic Rhinitis (PAR) | 200 |
| AVEO Pharmaceuticals, Inc. | Phase 3 | Cachexia; Cancer; Cachexia; Cachexia-Anorexia Syndrome; Metastatic Colorectal Cancer (CRC); Metastatic Non-small Cell Lung Cancer (NSCLC); Weight Loss | 950 |
| Pfizer | Phase 3 | Early Breast Cancer; Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | 3800 |
| Fosun Pharmaceutical Industrial Development (Shenzhen) Co., Ltd. | Phase 2 | sHTG; HTG With ASCVD (Diagnosed or at Increased Risk) | 192 |
| Atom Therapeutics Co., Ltd | Phase 2 | Chronic Kidney Disease | 80 |
| Prana Therapies Inc | Phase 2 | Atopic Dermatitis (AD) | 39 |
| Puma Biotechnology, Inc. | Phase 2 | Small Cell Lung Cancer ( SCLC ) | 50 |
| BeOne Medicines | Phase 2 | Advanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma | 30 |
| Hansoh BioMedical R&D Company | Phase 2 | Non-Small Cell Lung Cancer | 76 |
| Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Phase 2 | Advanced Solid Tumors | 63 |
| Galderma R&D | Not applicable (device, behavioral) | Jawline Definition | 162 |
| Antev Ltd. | Phase 2 | Endometriosis Pelvic; Endometriosis Ovaries; Premenopausal; Endometriosis (Diagnosis); Dysmenorrhoea; Dyspareunia (Female) | 84 |
| MIBIO PTE. LTD. | Phase 3 | Thrombocytopenia Associated With Chronic Liver Disease | 150 |
| Beijing Mabworks Biotech Co., Ltd. | Phase 2 | Multiple Myeloma | 78 |
| Grünenthal GmbH | Phase 2 | Duchenne Muscular Dystrophy (DMD) | 36 |
| GlaxoSmithKline | Phase 2 | Carcinoma | 41 |
| Alexion Pharmaceuticals, Inc. | Phase 2 | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 78 |
| Cristcot LLC | Phase 2 | Hemorrhoidal Disease | 78 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 2 | Idiopathic Pulmonary Fibrosis (IPF) | 75 |
| Hoffmann-La Roche | Observational | Relapsing-Remitting Multiple Sclerosis | 1800 |
| A.M.I. Agency for Medical Innovations GmbH | Not applicable (device, behavioral) | Pelvic Organ Prolapse (POP); Synthetic Mesh; Laparoscopic Surgery; Gynecologic Laparoscopic Surgery; Sacrocolpopexy; Pelvic Floor Prolapse | 100 |
| Suzhou HepaThera Biotech Co., Ltd. | Phase 2 | Chronic Hepatitis B | 86 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | 75 |
| X4 Pharmaceuticals | Phase 2 | Acquired Primary Autoimmune and Idiopathic Chronic Neutropenia Disorders; Chronic Neutropenia; Autoimmune Neutropenia; Chronic Idiopathic Neutropenia | 40 |
| Aperta Biosciences, LLC | Phase 2 | Blepharitis | 15 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 3 | First-line pMMR Endometrial Cancer | 333 |
| EIP Pharma Inc | Phase 2 | Moderate to Severe Acute Ischaemic Stroke; Ischaemic Stroke | 45 |
| Mabsoft Therapeutics (Shanghai) Co., Ltd. | Phase 1 | Neoplams | 420 |
| Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 2 | Asthma | 160 |
| Laboratorios Silanes S.A. de C.V. | Phase 3 | Primary Dysmenorrhea | 130 |
| Aperta Biosciences, LLC | Phase 2 | Blepharitis | 66 |
| Hanmi Pharmaceutical Company Limited | Phase 3 | Erectile Dysfunction | 225 |
| Medsyn Biopharma, LLC | Phase 2 | Triple-Negative Breast Cancer (TNBC); Gastric Cancer (GC); Gastric Cancer Adenocarcinoma Metastatic; Ovarian Cancer Metastatic; Ovarian Cancer Metastatic Recurrent; Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) | 75 |
| AstraZeneca | Phase 3 | Small Cell Lung Carcinoma | 71 |
| AbbVie | Phase 2 | Extensive Stage-Small Cell Lung Cancer (ES-SCLC) | 80 |
| Healthgen Biotechnology Corp. | Phase 2 | Gastric Mucosal Lesion | 40 |
| Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Phase 2 | Atopic Dermatitis (AD) | 160 |
| Editas Medicine, Inc. | Phase 2 | Heterozygous Familial Hypercholesterolemia (HeFH) | 56 |
| Merck Sharp & Dohme LLC | Phase 2 | Rheumatoid Arthritis | 60 |
| AbbVie | Phase 2 | Extensive Stage-Small Cell Lung Cancer | 80 |
| Changchun BCHT Biotechnology Co. | Phase 2 | Pertussis (Whooping Cough); Diphtheria; Tetanus | 420 |
| Ipsen | Phase 3 | Primary Biliary Cholangitis | 18 |
| AN2 Therapeutics, Inc | Phase 2 | Polycythemia Vera (SNOMED CT: 109992005) | 75 |
| Danisco | Phase 2 | Digestive Symptoms; Gastrointestinal Symptoms; Healthy; Impaired Pancreatic Function | 50 |
| McNeil AB | Phase 2 | Smoking Cessation; Nicotine Replacements Therapy | 280 |
| Chongqing Peg-Bio Biopharm Co., Ltd. | Phase 2 | Thrombocytopenia Associated With Chronic Liver Disease | 54 |
| Pharmasaga Co. Ltd. | Phase 2 | Type 1 Diabetes Mellitus | 36 |
| Serum Institute of India Pvt. Ltd. | Phase 2 | Human Papillomavirus Infection | 72 |
| Biogen | Phase 2 | Immunoglobulin A Nephropathy | 25 |
| Jiangsu Guiqiong Pharmaceutical Co., Ltd. | Phase 2 | Cachexia-Anorexia Syndrome; Cachexia; Cancer | 96 |
| Corium Innovations, Inc. | Phase 1 | Major Depressive Disorder (MDD) | 232 |
| Viatris Inc. | Phase 4 | Allergic Rhinitis Due to Allergens | 100 |
| Janssen Pharmaceutica N.V., Belgium | Observational | Relapsed/Refractory Multiple Myeloma | 256 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Observational | Multiple Sclerosis | 366 |
| Jiangsu Simcere Pharmaceutical Co., Ltd. | Phase 1 | ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 270 |
| Teva Branded Pharmaceutical Products R&D LLC | Observational | Schizophrenia | 1085 |
| Janssen-Cilag International NV | Observational | Psoriasis | 135 |
| Janssen Pharmaceutica N.V., Belgium | Observational | Arthritis, Psoriatic | 1314 |
| Hellenic Institute for the Study of Sepsis | Phase 3 | Sepsis | 398 |
| Applied Biology, Inc. | Phase 3 | Androgenetic Alopecia; Female Pattern Baldness; Male Pattern Baldness | |
| HALEON | Observational | Pain | 2100 |
| GlaxoSmithKline | Phase 4 | Hepatitis B | 303 |
| Vascutek Ltd. | Observational | Aortic Aneurysm and Dissection | 150 |
| Amgen | Phase 1 | Psoriasis; Arthritis, Psoriatic; Oral Ulcer | 114 |
| Beta Bionics, Inc. | Not applicable (device, behavioral) | Diabetes (Insulin-requiring, Type 1 or Type 2) | 400 |
| Galderma R&D | Not applicable (device, behavioral) | Cheek Wrinkles; Midface Contour Deficiencies | 326 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | Tuberculosis | 144 |
| AstraZeneca | Phase 4 | Chronic Kidney Disease | 731 |
| Takeda | Observational | Narcolepsy Type 1; Narcolepsy Type 2 | 402 |
| Hoffmann-La Roche | Phase 1 | Solid Tumors | 540 |
| Ahn-Gook Pharmaceuticals Co.,Ltd | Observational | Hypertension (HTN); Hypertension; Essential (Primary) Hypertension | 4528 |
| Zoll Medical Corporation | Observational | Central Sleep Apnea (Diagnosis); Central Sleep Apnea Syndrome; Central Sleep Apnea; Phrenic Nerve Stimulation; Sleep Disordered Breathing (SDB); Sleep Apnea, Central | 300 |
| Helix Surgical | Observational | Cataract Surgery | 106 |
| West China Hospital | Phase 2 | Radiation-induced Dermatitis | 140 |
| Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Solid Tumors | 604 |
| Beeline Medicines Corporation | Phase 1 | Healthy Volunteers (no Disease Condition Under Study) | 104 |
| Takeda | Observational | Narcolepsy Type 1 | 400 |
| CareDx | Not applicable (device, behavioral) | Heart Transplant Rejection | 200 |
| bioLytical Laboratories | Not applicable (device, behavioral) | HCV Infection | 388 |
| Axomove | Not applicable (device, behavioral) | Obese Adults | 184 |
| bioLytical Laboratories | Not applicable (device, behavioral) | HCV Infection | 1660 |
| Superluminal Medicines, Inc. | Phase 1 | Healthy Participants | 138 |
| Merck Sharp & Dohme LLC | Phase 1 | Healthy | 330 |
| Bayer | Observational | Chronic Heart Failure With Reduced Ejection Fraction; Worsening Chronic Heart Failure | 604 |
| Medtronic - MITG | Observational | Prostatectomy; Cystectomy; Nephrectomy; Urologic Cancer | 110 |
| Swiss Cancer Institute | Phase 3 | Metastatic NSCLC - Non-Small Cell Lung Cancer | 230 |
| Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Atopic Dermatitis | 18 |
| GlaxoSmithKline | Phase 1 | Pneumonia, Bacterial | 122 |
| Boston Scientific Corporation | Observational | Paroxysmal AF | 501 |
| Swiss Cancer Institute | Phase 2 | Melanoma; Advanced Melanoma | 108 |
| Pfizer | Observational | Metastatic Urothelial Carcinoma; Urothelial Cancer; Urothelial Carcinoma; Locally Advanced or Metastatic Urothelial Carcinoma; Bladder Cancer; Bladder Neoplasms | 5122 |
| Hansoh BioMedical R&D Company | Phase 1 | Non-Small Cell Lung Cancer | 102 |
| BeOne Medicines | Phase 1 | Advanced Solid Tumor | 137 |
| Pfizer | Phase 1 | Advanced Breast Cancer; Advanced or Metastatic Breast Cancer; Metastatic Breast Cancer (HR+/ HER2-); Metastatic Colorectal Adenocarcinoma | 268 |
| RECORDATI GROUP | Observational | Neuroblastoma | 125 |
| AstraZeneca | Observational | Atypical Hemolytic Uremic Syndrome(aHUS) | 367 |
| Asian Institute of Gastroenterology, India | Phase 3 | Pancreatitis, Chronic; Exocrine Pancreatic Insufficiency (EPI) | 134 |
| University College, London | Phase 3 | Tuberculosis (TB) | 784 |
| InventisBio Yiqi Beijing Limited | Phase 1 | Solid Tumor (Phase I); Ovarian Cancer; NSCLC (Advanced Non-small Cell Lung Cancer); TNBC - Triple-Negative Breast Cancer | 204 |
| Novo Nordisk A/S | Phase 1 | Diabetes Mellitus, Type 2 | 121 |
| Pfizer | Phase 1 | Pneumococcal Disease | 200 |
| Boston Scientific Corporation | Observational | Atrial Fibrillation; Pulsed Field Ablation; FARAPULSE | 550 |
| Boston Scientific Corporation | Observational | Atrial Fibrillation (AF) | 524 |
| AstraZeneca | Observational | Ovarian Cancer | 256 |
| Hansoh BioMedical R&D Company | Phase 1 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | 338 |
| BioNTech SE | Phase 1 | Advanced Solid Tumors | 207 |
| Immunome, Inc. | Phase 1 | Colorectal Cancer; Non-Small Cell Lung Cancer; Small Cell Lung Cancer; Neuroendocrine Neoplasm | 200 |
| Janssen Korea, Ltd., Korea | Observational | Pulmonary Arterial Hypertension | 333 |
| Sinovac Biotech Co., Ltd | Phase 1 | Seasonal Influenza | 175 |
| Hrain Biotechnology Co., Ltd. | Observational | B-Cell Non-Hodgkin Lymphoma (NHL) | 200 |
| AMCG | Observational | Coronary Artery Disease | 165 |
| Fujian Medical University Union Hospital | Phase 3 | Acute Ischemic Stroke; Large Vessel Occlusion | 1266 |
| Arjil Pharmaceuticals LLC | Phase 2 | Dermatitis Atopic | 40 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | Tuberculosis, MDR | 5832 |
| First Affiliated Hospital of Wannan Medical College | Phase 3 | Ischemia Stroke; TIA (Transient Ischemic Attack) | 520 |
| Ruijin Hospital | Phase 3 | Non-Small Cell Lung Cancer | 140 |
| Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Phase 2 | Dyslipidemia | 160 |
| Tata Memorial Hospital | Phase 3 | Gastroenteropancreatic Neuroendocrine Tumors | 123 |
| Ruijin Hospital | Phase 3 | Non-Small-Cell Lung Cancer | 276 |
| Jiangsu Jingze Biopharmaceutical Co., Ltd. | Phase 2 | Vitreomacular Traction (VMT) | 48 |
| Beni-Suef University | Phase 2 | Iron Deficiency Anemia (IDA); ESRD (End Stage Renal Disease) | 108 |
| Boston Scientific Corporation | Not applicable (device, behavioral) | Motor Epilepsy | 10 |
| Qufora A/S | Not applicable (device, behavioral) | Faecal Incontinence; Chronic Constipation | 66 |
| Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal | Phase 3 | Giant Cell Arteritis (GCA); Acute Coronary Syndrome (ACS); Ishemic and Thrombotic Complications | 120 |
| University of Calgary | Phase 3 | Stroke, Acute Ischemic; Medium Vessel Occlusion | 800 |
| Juro Sciences Inc. | Phase 2 | Participants With Underactive Bladder (UAB) | 70 |
| Henan Cancer Hospital | Phase 2 | Locally Advanced Resectable Rectal Cancer | 155 |
| International AIDS Vaccine Initiative | Phase 2 | Tuberculosis (TB) | 5531 |
| TRB Chemedica International SA | Not applicable (device, behavioral) | Dry Eye Disease | 80 |
| Arovella Therapeutics Ltd | Phase 1 | Non Hodgkin Lymphoma (NHL); Leukaemia | 46 |
| Beijing Tiantan Hospital | Phase 2 | Parkinson Disease (PD); Sleep Initiation and Maintenance Disorders; Deep Brain Stimulation | 128 |
| Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | Phase 2 | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | 384 |
| Sun Yat-sen University | Phase 2 | Nasopharyngeal Cancinoma (NPC) | 214 |
| Beijing Tiantan Hospital | Phase 2 | Brain Neoplasms; Sleep Initiation and Maintenance Disorders | 112 |
| George Washington University | Phase 2 | Obesity & Overweight; Respiratory Depression; Intranasal Drug Administration; Oxytocin; Bariatric Surgery | 100 |
All ClinicalTrialStartPulse record reports